A multicentric randomized controlled trial on the impact of lengthening the interval between neoadjuvant radiochemotherapy and surgery on complete pathological response in rectal cancer (GRECCAR-6 trial): rationale and design

被引:28
作者
Lefevre, Jeremie H. [1 ,2 ]
Rousseau, Alexandra [3 ]
Svrcek, Magali [2 ,4 ]
Parc, Yann [1 ,2 ]
Simon, Tabassome [2 ,3 ]
Tiret, Emmanuel [1 ,2 ]
机构
[1] Hop St Antoine, AP HP, Dept Digest Surg, F-75012 Paris, France
[2] Univ Paris 06, Paris, France
[3] Hop St Antoine, AP HP, Dept Clin Pharmacol, Clin Res Unit URC Est, F-75012 Paris, France
[4] Hop St Antoine, AP HP, Dept Pathol, F-75012 Paris, France
来源
BMC CANCER | 2013年 / 13卷
关键词
Rectal cancer; Radiochemotherapy; Complete histological response; Procedure; TOTAL MESORECTAL EXCISION; COMBINED-MODALITY THERAPY; PREOPERATIVE RADIOTHERAPY; PROGNOSTIC-SIGNIFICANCE; LOCAL RECURRENCE; SURGICAL COMPLICATIONS; CHEMORADIATION; CHEMORADIOTHERAPY; SURVIVAL; RESECTION;
D O I
10.1186/1471-2407-13-417
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Neoadjuvant radiochemotherapy (RCT) is now part of the armamentarium of cancer of the lower and middle rectum. It is recommended in current clinical practice prior to surgical excision if the lesion is classified T3/T4 or N+. Histological complete response, defined by the absence of persistent tumor cell invasion and lymph node (ypT0N0) after pathological examination of surgical specimen has been shown to be an independent prognostic factor of overall survival and disease-free survival. Surgical excision is usually performed between 6 and 8 weeks after completion of CRT and pathological complete response rate ranges around 12%. In retrospective studies, a lengthening of the interval after RCT beyond 10 weeks was found as an independent factor increasing the rate of pathological complete response (between 26% and 31%), with a longer disease-free survival and without increasing the operative morbidity. The aim of the present study is to evaluate in 264 patients the rate of pathological complete response rate of rectal cancer after RCT by lengthening the time between RCT and surgery. Methods/design: The current study is a multicenter randomized trial in two parallel groups comparing 7 and 11 weeks of delay between the end of RCT and cancer surgery of rectal tumors. At the end of the RCT, surgery is planified and randomization is performed after patient's written consent for participation. The histological complete response (ypT0N0) will be determined with analysis of the complete residual tumor and double reading by two pathologists blinded of the group of inclusion. Patients will be followed in clinics for 5 years after surgery. Participation in this trial does not change patient's management in terms of treatment, investigations or visits. Secondary endpoints will include overall and disease free survival, rate of sphincter conservation and quality of mesorectal excision. The number of patients needed is 264.
引用
收藏
页数:8
相关论文
共 44 条
  • [1] [Anonymous], METHODES BIOSTATISTI
  • [2] INTERIM ANALYSIS IN CLINICAL-TRIALS
    ARMITAGE, P
    [J]. STATISTICS IN MEDICINE, 1991, 10 (06) : 925 - 937
  • [3] Chemotherapy with preoperative radiotherapy in rectal cancer
    Bosset, Jean-Francois
    Collette, Laurence
    Calais, Gilles
    Mineur, Laurent
    Maingon, Philippe
    Radosevic-Jelic, Ljiljana
    Daban, Alain
    Bardet, Etienne
    Beny, Alexander
    Ollier, Jean-Claude
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (11) : 1114 - 1123
  • [4] Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: Preliminary results - EORTC 22921
    Bosset, JF
    Calais, G
    Mineur, L
    Maingon, P
    Radosevic-Jelic, L
    Daban, A
    Bardet, E
    Beny, A
    Briffaux, A
    Collette, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) : 5620 - 5627
  • [5] Incidence of gastrointestinal cancers in France
    Bouvier, AM
    Remontet, L
    Jougla, E
    Launoy, G
    Grosclaude, P
    Buémi, A
    Tretarre, B
    Velten, M
    Dancourt, V
    Menegoz, FO
    Guizard, AV
    Lesec'h, JM
    Peng, J
    Bercelli, P
    Arveux, P
    Estève, J
    Faivre, J
    [J]. GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2004, 28 (10): : 877 - 881
  • [6] Bujko K, 2012, DIS COLON RECTUM, V55, pE31, DOI 10.1097/DCR.0b013e31823f86cb
  • [7] The Clavien-Dindo Classification of Surgical Complications Five-Year Experience
    Clavien, Pierre A.
    Barkun, Jeffrey
    de Oliveira, Michelle L.
    Vauthey, Jean Nicolas
    Dindo, Daniel
    Schulick, Richard D.
    de Santibanes, Eduardo
    Pekolj, Juan
    Slankamenac, Ksenija
    Bassi, Claudio
    Graf, Rolf
    Vonlanthen, Rene
    Padbury, Robert
    Cameron, John L.
    Makuuchi, Masatoshi
    [J]. ANNALS OF SURGERY, 2009, 250 (02) : 187 - 196
  • [8] Pathologic Complete Response After Neoadjuvant Treatment for Rectal Cancer Decreases Distant Recurrence and Could Eradicate Local Recurrence
    de Campos-Lobato, Luiz Felipe
    Stocchi, Luca
    Moreira, Andre da Luz
    Geisler, Daniel
    Dietz, David W.
    Lavery, Ian C.
    Fazio, Victor W.
    Kalady, Matthew F.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (06) : 1590 - 1598
  • [9] Neoadjuvant Therapy for Rectal Cancer: The Impact of Longer Interval Between Chemoradiation and Surgery
    de Campos-Lobato, Luiz Felipe
    Geisler, Daniel P.
    Moreira, Andre da Luz
    Stocchi, Luca
    Dietz, David
    Kalady, Matthew F.
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2011, 15 (03) : 444 - 450
  • [10] Classification of surgical complications - A new proposal with evaluation in a cohort of 6336 patients and results of a survey
    Dindo, D
    Demartines, N
    Clavien, PA
    [J]. ANNALS OF SURGERY, 2004, 240 (02) : 205 - 213